Wedbush Reaffirms Outperform Rating for Keros Therapeutics (NASDAQ:KROS)
Wedbush reiterated their outperform rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report sent to investors on Thursday morning,RTT News reports. They currently have a $84.00 target price on the stock. Wedbush also issued estimates for Keros Therapeutics’ Q3 2024 earnings at ($1.31) EPS, Q4 2024 earnings at ($1.36) EPS, […]
More Stories
What Time Does Netflix Release Shows? Don’t Miss Another New Release
Many of us like to watch series and movies, but most of the time miss the new release, right? And...
Trump Calls Iran’s Response to Peace Proposal ‘Totally Unacceptable’
By Tom Gantert U.S. President Donald Trump on May 10 rejected Iran’s response to the latest peace proposal pitched by...
Iran Turns to China Rail Link to Bypass US Blockade, but It Has Limited Effect, Analysts Say
By Alex Wu As the U.S. military continues to blockade Iranian ports, Iran has increased overland railway shipment with China...
Passengers Evacuate Cruise Ship Hit by Deadly Hantavirus Outbreak
By Tom Gantert The passengers and crew aboard the MV Hondius exited the hantavirus-stricken cruise ship in the Canary Islands...
Hantavirus Symptoms Reported on Cruise Evacuation Flight
By Tom Gantert A French citizen on the MV Hondius cruise ship came down with hantavirus symptoms while flying back...
Less Than 11 Percent of New Construction Is in Urban Areas, Report Finds
By Mary Prenon Newly built homes across America are scarce in urban areas and carry a significant price premium, according...